Management of metastatic prostatic cancer.

Published

Journal Article

Current management techniques for metastatic prostatic cancer have given rise to controversies regarding the optimal timing, form, and degree of androgen deprivation. Low-dose diethylstilbestrol (DES) or orchiectomy decrease serum testosterone levels while posing less cardiovascular risk than high-dose DES. LH-RH analogues, such as leuprolide or buserelin, also inhibit testosterone production. Some studies suggest that some tumor cells may be relatively, rather than absolutely, androgen dependent. This has been the rationale for the combined use of a pure antiandrogen and an LH-RH agonist. Unfortunately, while this combination has been found effective in previously untreated patients, it has not been equally effective in those who have undergone prior therapy and demonstrated disease progression.

Full Text

Duke Authors

Cited Authors

  • Paulson, DF

Published Date

  • February 1985

Published In

Volume / Issue

  • 25 / 2 Suppl

Start / End Page

  • 49 - 52

PubMed ID

  • 3918376

Pubmed Central ID

  • 3918376

International Standard Serial Number (ISSN)

  • 0090-4295

Language

  • eng

Conference Location

  • United States